Merck revealed Friday it started up its first late-stage clinical program for an oral PCSK9 inhibitor for cholesterol.
The program is currently enrolling participants in two registrational studies for MK-0616, which aims to lower LDL cholesterol. An outcomes study is also set to start this year,…
Click here to view original post
